Radiopharmaceuticals have attracted significant attention for their potential to enable a precision approach that overcomes challenges in conventional cancer treatments. However, existing radioisotopes still face issues such as serious side effects due to difficulties in controlling pharmacokinetics and constraints in drug design. Linqmed's radioisotope, 64Cu, retains the high cancer cell-killing efficacy equivalent to existing radioisotopes while addressing both the challenges of targeting difficult-to-treat cancers and minimizing side effects. Additionally, it emits positrons that enable PET diagnosis, providing the groundbreaking capability to "treat while observing" the therapeutic effect in real time. With this technology, Linqmed aims to provide innovative "visible" anti-cancer drugs to patients with refractory cancers, including glioblastoma.